CD274 and neoplasm: A phase 2 study confirmed the safety and efficacy of low-dose ipilimumab (1 mg/kg every 6 weeks) plus nivolumab (3 mg/kg every 2 weeks), and found that response rates were higher in patients with tissue tumor mutational burden (tTMB) ≥10 mutations per megabase (mut/Mb), regardless of PD-L1 status (114).